Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

Karin Jordan, Axel Grothey, Wilfried Grothe, Thomas Kegel, Hans Heinrich Wolf, Hans Joachim Schmoll

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalEuropean Journal of Haematology
Issue number3
StatePublished - Mar 2005


  • CD20
  • EBV-associated lymphoproliferative disease
  • Liebow granulomatosis
  • Lymphomatoid granulomatosis
  • Mediastinal bulk
  • Rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy'. Together they form a unique fingerprint.

Cite this